Genetic Diseases of the Kidney

National Academies: Optimizing US Investment in Academic Research

This updated report from the National Academies of Science, Engineering and Medicine addresses upcoming changes to the Common Rule governing many human research policies, and the need to streamline regulations and eliminate redundancies to enable research advances to move forward as quickly as possible.


ASN President's Column July 2016

In this month's column, ASN President Raymond C. Harris, MD, FASN discusses initiatives that are changing the practice landscape in nephrology.

Kidney Disease is the 9th Leading Cause of Death in the US

Kidney disease is the 9th leading cause of death in the US, according to the Centers for Disease Control and Prevention.

First CRISPR Clinical Trial Receives Advisory Panel Approval

First CRISPR clinical trial could start by the end of this year.

Automating DNA Origami Opens Doors to Many Uses

Using strands of DNA researchers can build complex, nanometer-scale structures, but the process is complex and has limited the technique, known as DNA origami, to just a small group of experts in the field.

ASN Names Next Editor-in-Chief of CJASN

ASN has named Rajnish Mehrotra, MD, FASN, as CJASN Editor-in-Chief effective January 1, 2017. He will serve a six-year term.

Communities at ASN

ASN Communities offer multiple opportunities to connect with colleagues working in the areas that interest you most. Check out this rapidly growing and dynamic ASN initiative here.

Gene Editing Technology

Check out the resources on gene editing: background, pros and cons, potential clinical applications.

mTOR Kinase Inhibitor Slows ADPKD Progression in Animal Model

In a rat model of autosomal dominant polycystic kidney disease (ADPKD), treatment with an mTOR kinase inhibitor called PP242 decreased proliferation in cystic and non-cystic tubules, inhibited renal enlargement and cystogenesis, and significantly reduced the loss of kidney function. The findings are published in Nephrology Dialysis Transplantation. The mTOR pathway consists of mTOR complex 1 and mTOR complex 2 and is activated in PKD kidneys. mTOR kinase inhibitors target both mTOR complexes.

Investigators Reveal Potential Mechanisms Behind Congenital Kidney Condition

Researchers have found that an increased response to sympathetic nerve activity and an inability to respond to nitric oxide, a factor important for blood vessel health, may promote kidney injury and cardiovascular disease in infants born with small kidneys. Children born with reduced congenital renal mass have an increased risk of hypertension and CKD in adulthood, but the mechanisms involved have been poorly understood. The Circulation study, which was conducted in sheep, provides new insights.